AddedRisk Factors
We are expanding our operations outside the United States, which increases operational complexity and may require significant management attention and resources. Our international operations involve increased logistics and supply chain complexity, foreign customs and trade requirements, and reliance on third-party service providers, which may result in delays or increased costs. Operating internationally also exposes us to legal and compliance risks, as well as differing healthcare systems and reimbursement frameworks that may limit adoption of our OCS technologies, NOP services or related offerings or reduce expected revenues and margins, If we are unable to effectively manage these risks, our business, financial conditions and results of operations could be materially and adversely affected.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
Our use of artificial intelligence, or AI, and other emerging technologies could adversely impact our business and financial results.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
We currently make limited use of AI technologies in our operations, and we may continue to explore further use cases. The rapid advancement of these technologies presents opportunities for us in research, manufacturing, commercialization, and other business endeavors, but also entails risks, including that AI-generated content, analyses, or recommendations we utilize could be deficient, that our competitors may more quickly or effectively adopt AI capabilities, or that our use of AI or other emerging technologies increases regulatory, privacy, cybersecurity and other significant risks. In addition, any disruption or failure in the AI functionality we incorporate into our business activities, products or services could adversely impact our business or result in delays or errors in our product offerings. The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain, including in the areas of intellectual property, cybersecurity and privacy and data protection. Compliance with new or changing laws, regulations or industry standards relating to AI may impose significant costs on us and limit our ability to effectively develop, deploy or use AI technologies. Furthermore, if we are unable to effectively manage the use of AI technologies by our employees and service providers, our confidential information, intellectual property and reputation could be put at risk. Failure to appropriately respond to this evolving landscape may result in reputational, competitive and business harm as well as litigation and regulatory action and fines, penalties and expenses related thereto.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete. Patent litigation and other proceedings may also absorb significant management time.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedRisk Factors
•the costs incurred in our efforts to operate and grow our NOP, including the costs and timing of growing our logistics capabilities, inclusive of acquiring and maintaining current and additional aircraft for our aviation transportation services;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Furthermore, our ability to utilize our NOLs or credits is conditioned upon our maintaining profitability and generating U.S. federal and state taxable income. As described above, prior to 2024, we incurred significant net losses since inception; and therefore, we do not know whether we will generate the U.S. federal or state taxable income necessary to utilize our NOL or credit carryforwards. Under the Tax Cuts and Jobs Act, or TCJA, NOLs arising in taxable years beginning after December 31, 2017 will not be subject to expiration. In addition, the deduction for NOLs in any taxable year is limited to 80% of annual taxable income in respect of NOLs generated during or after 2018. The TCJA also reduced the corporate income tax rate to 21%, from a prior rate of 35%. This may cause a reduction in the potential economic benefit of our NOLs and other available deferred tax assets.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
We have a limited history of providing aviation transportation services and we continue to depend on certain members of the former management team of Summit for the successful operation and integration into our NOP services offering. Even if we are able to utilize the Bridge to Life Assets and fully realize the benefits of our acquisition of Summit, we may not realize the expected
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedRisk Factors
We expect our operating and capital expenditures will continue to increase for the foreseeable future as we focus on growing commercial sales of our products in both the U.S. and select non-U.S. markets, including growing our NOP; acquiring and maintaining additional aircraft to support aviation transportation; growing expanding our commercial team, which will pursue increasing commercial sales of growing our OCS products; NOP, scaling our manufacturing operations; and sterilization operations, continuing research, development and clinical trial efforts, including expanding our research and development and manufacturing capabilities in Italy, seeking regulatory approval for our the next generation OCS products, including conducting clinical trials for our next generation OCS products; and seeking regulatory clearance for OCS, new products and product enhancements, including new indications, both in both the U.S. United States and in select non-U.S. markets. markets, establishing and relocating to a new long-term global headquarters, and seeking greater control of air and ground transport for our NOP.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, if these If our single or sole-source suppliers are unable or unwilling to deliver components to us, whether due to a labor shortage, slow down or stoppage, or for any other reason, we would may not be required able to seek alternative suppliers. manufacture or have available one or more products during such period of unavailability and our business could suffer, possibly materially.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, in July 2020, the Court of Justice of the European Union invalidated the U.S.-EU Privacy Shield Framework, which has led There continues to increased be heightened scrutiny of data transfers from the EEA and the UK to the United States generally generally, as well as other jurisdictions, and this may increase our costs of compliance with data privacy legislation.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, in July 2020, the Court of Justice of the European Union invalidated the U.S.-EU Privacy Shield Framework, which has led to increased scrutiny of data transfers from since been replaced by the EEA and the UK to the United States generally and may increase our costs of compliance with data privacy legislation. EU-U.S.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, a corporation that undergoes an “ownership change,” generally defined in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an “ownership change,” generally defined as a greater than 50% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs, NOLs and its research and development credit carryforwards and its disallowed interest expense carryovers to offset future taxable income.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we are unable to obtain patent term extension or restoration or extension, the term of any such extension is less than we request, or the scope of patent protection is less than we would expect it to be during extension period, the period during which we can could enforce our patent rights for the applicable product will may be shortened and our competitors may obtain approval of competing products following our patent expiration. sooner.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
To be placed on the market in Great Britain after this date, medical devices must have undergone a conformity assessment in accordance with UK legislation and have the UKCA mark affixed. affixed (although the UK Government has announced its intent to consult on the indefinite recognition of the CE mark, which may change the time frame for UKCA mark requirements).
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
As we grow our international presence, we are increasingly exposed subject to trade and economic anti-corruption laws, anti-money laundering laws, export control laws, customs laws, sanctions laws and other restrictions laws and regulations imposed by the United States, the European Union and other governments and organizations. organizations in countries where we operate.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
The data we collect from our prior, ongoing and planned clinical studies and patient registry may not be deemed sufficient for this purpose in to support a coverage determination finding by CMS or a Medicare contractor. contractor that use of the OCS is reasonable and necessary such that coverage is warranted.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, we are subject to the requirements of the GDPR, which imposes more stringent administrative requirements for controllers and processors of personal data, including, for example, shortened demanding timelines for notifying personal data breach notifications, breaches, limitations on retention of personal information, increased stringent requirements pertaining to the processing of health data and data, rules regulating pseudonymized (i.e., key-coded) data, additional obligations when we contract with service providers, provider processors, and more robust rights for individuals over with respect to their personal data.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our products have been and may in the future be subject to product recalls that U.S. federal government shutdowns could harm our reputation and could materially and adversely affect our business, financial condition, operating results, cash flows and prospects.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Proceedings challenging our patents could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Alternatively, if the Business Litigation Session of the Superior Court of Suffolk County, Massachusetts or a court outside of Massachusetts were to find this exclusive forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings described above, we may incur additional costs associated with resolving such matters in other venues or jurisdictions, which could materially and adversely affect our business, financial condition, operating results, cash flows and prospects.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
HRSA has consistently exercised options to extend the contract for UNOS to operate OPTN, albeit in a more limited capacity, since March 2024. Most recently, in December 2025, HRSA and UNOS reached a new agreement that took effect on December 30, 2025. This contract allows HRSA to extend UNOS’ work for up to 12 months, until December 29, 2026, structured as four optional three-month periods. The new agreement reflects a shift of several former UNOS functions, including patient safety, reporting and tracking of donor-derived transmission events, and committee support, to HRSA or other contractors.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
HRSA continues to implement efforts to improve and modernize the OPTN, including enhancements to patient data on organ procurement, expanded transparency through a publicly accessible data dashboard for allocation out of sequence (AOOS) events, expanded outreach and financial support for living organ donors, and a new OPTN fee collection process whereby HRSA directly collects and distributes patient registration fees under authorities originally granted by the 2025 Full-Year Continuing Appropriations and Extensions Act and extended by the 2026 Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act. The impact that HRSA's initiatives and the U.S. Organ Procurement and Transplantation Network Act may have on our business, including on our NOP, is uncertain at this time.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Research, development and clinical trials expenses consist of costs incurred for research activities, product development, hardware and software engineering and clinical trial activities, including salaries and related costs, including stock-based compensation, facilities costs, laboratory supplies, depreciation, testing, regulatory, data management and consulting costs.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Our (provision) benefit for income taxes is based on taxable income (loss), applicable income tax rates, net research and development tax credits, net operating loss carryforwards, changes in valuation allowance estimates and deferred income taxes. During the fourth quarter of 2025, we concluded that it was more likely than not that we will realize substantially all of our net U.S. federal and state deferred tax assets and accordingly, recognized a benefit to income tax expense of $103.3 million related to the release of our valuation allowance. We relied primarily on cumulative income over the preceding twelve quarters, recent operating profits and, to a lesser extent, expected future profits in our assessment to release the valuation allowance. We maintained a valuation allowance of $0.9 million on certain state tax attributes as we considered it more-likely-than-not that these tax attributes would expire before realization.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
As a result of the release of our valuation allowance we expect our income tax rate will increase in the future. To the extent allowed, we intend to use our available net operating loss carryforwards and tax credits to reduce cash tax payment obligations.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Total selling, general and administrative expenses increased by $16.6 million from $168.6 million in the year ended December 31, 2024 to $185.2 million in the year ended December 31, 2025. Personnel related costs increased by $5.0 million primarily due to an increase in stock-based compensation expense of $3.2 million and increases in contractor and recruiting costs to support the growth of our organization, partially offset by a decrease in personnel costs due to less time spent supporting marketing, finance and administrative activities. Personnel related costs included stock-based compensation expense of $30.8 million and $27.6 million for the years ending December 31, 2025 and 2024, respectively. Professional and consultant fees increased by $7.6 million due primarily to increased audit and tax-related fees and legal costs related to patents as well as increased professional and legal fees related to an independent review of business practices following allegations raised in a short seller report released in January 2025. We also incurred higher consulting services related to general business initiatives to support our growth. Facility related and other costs increased by $9.4 million due primarily to increased depreciation and amortization and information technology infrastructure costs as well as increases in non-income based state taxes. These increases were partially offset by a decrease in NOP support costs of $5.5 million due primarily to less activity supporting selling, general and administrative functions.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
We had an income tax benefit of $82.8 million for 2025, as compared to a provision for income tax of $0.3 million in 2024. Our effective tax rate was (77.0%) and 0.9% for 2025 and 2024, respectively. Our effective tax rate for 2025 differs from the U.S. federal statutory income tax rate of 21.0% primarily due to the release of a U.S. valuation allowance. In the fourth quarter of 2025, we concluded that it is more likely than not that substantially all of our U.S. deferred tax assets are realizable, resulting in a valuation allowance release of $103.3 million. Our effective tax rate for 2024 differs from the U.S. federal statutory income tax rate of 21.0% primarily due to excess stock compensation deductions, partially offset by state and federal income taxes for the portion of our taxable income that was not offset by operating loss and tax credit carryforwards, and the impact from the change in valuation allowance.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
•the cost of constructing research and development and manufacturing facilities in Italy;
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
•the costs related to establishing and relocating to a new long-term global headquarters to accommodate the growing scale and complexity of our business.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
On January 8, 2026, we entered into a lease agreement for space in Somerville, Massachusetts to eventually replace our existing headquarters in Andover, Massachusetts. Base rent begins to accrue in the first quarter of 2028 and the initial lease term expires 192 months from the date base rent begins to accrue, unless earlier terminated. The annual base rent under this lease will initially be $23.9 million and will be subject to a 2% annual increase during the first three years of the initial lease term and a 3% annual increase for each year thereafter during the remainder of the initial lease term. On January 8, 2026, we acquired two parcels adjacent to the leased premises in Somerville, Massachusetts for a purchase price of $15.0 million for each property.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
In July 2025, we purchased two parcels of land in Mirandola, Italy. We plan to construct research and development and manufacturing facilities but have not yet entered into constructions contracts.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedMD&A
Prior to our acquisition in 2023, Summit derived its revenue primarily from charter flight services. To a lesser extent, Summit also derived revenue from providing flight school training, managing aircraft and other related services. As part of the Summit integration, we transitioned Summit's charter flight and aircraft management customers to third parties. We do not anticipate generating revenue from charter flights or aircraft management and related services. We are continuing to offer flight school training services. During the years ended December 31, 2024 and 2023 service revenue of $4.4 million and $4.9 million, respectively, was from Summit's legacy operations, unrelated to the NOP and organ transplant.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Research, development and clinical trials expenses consist primarily of costs incurred for our research activities, product development, hardware and software engineering, clinical trials to continue to develop clinical evidence of our products’ safety and effectiveness, regulatory expenses, testing, consultant services and other costs associated with our OCS technology platform and OCS products, which include:
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•employee-related expenses, including salaries, related benefits and stock-based compensation expense for employees engaged in research, hardware and software development, regulatory and clinical trial functions, and recruiting and temporary service fees related to such personnel;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•expenses incurred in connection with the clinical trials of our products, including under agreements with third parties, such as consultants, contractors and data management organizations;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•the cost of maintaining and improving our product designs, including the testing of materials and parts used in our products;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
IPR&D in 2023 was related to the acquisition of certain assets related to lung and heart perfusion technology from Bridge to Life Ltd. and its subsidiary Tevosol, Inc., together BTL.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Total selling, general and administrative expenses increased by $49.1 million from $119.6 million in the year ended December 31, 2023 to $168.6 million in the year ended December 31, 2024 due primarily to increases in personnel related costs, and facility related and other costs. Personnel related costs increased by $36.8 million primarily due to the continued expansion of our team to support the growth in our business. Stock-based compensation expense increased by $11.0 million, due primarily to additional grants to new and existing employees and the modification of stock awards pursuant to the transition agreement with our former Chief Financial Officer. Facility related and other costs increased by $11.3 million due primarily to increased costs associated with post-approval studies and information technology infrastructure costs, and depreciation and amortization expense due to the growth in our business. Professional and consultant fees increased by $0.9 million due primarily to increased fees in 2024 related to information technology and other enterprise solutions costs to support the growth in our business. Professional and consultant fees in the year ended December 31, 2023 included transaction costs of $2.0 million related to our Summit acquisition.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Income taxes for the years ended December 31, 2024 and 2023 included a tax provision of $0.3 million and less than $0.1 million, respectively, related to state and foreign income taxes. For the year ended December 31, 2023, we also recorded a tax benefit of $1.7 million for the release of a portion of our valuation allowance related to the net deferred tax liabilities recorded in purchase accounting. As part of the allocation of the purchase price of Summit, we recorded deferred tax liabilities for the differences between the fair value recognized in purchase accounting and the tax basis of property, plant and equipment and intangible assets. The net deferred tax liability is a source of income to support the recognition of a portion of our existing deferred tax assets. Therefore, we released the same amount of our valuation allowance. We maintain a valuation allowance on our overall net deferred tax asset as we deem it more likely than not that the net deferred tax asset will not be realized.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Changes in accounts receivable, inventory, prepaid expenses and other current assets, accounts payable, and accrued expenses and other current liabilities in each reporting period are generally due to growth in our business and timing of invoices and payments.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedMD&A
Net cash used provided by changes in our operating assets and liabilities for the year ended December 31, 2024 2025 consisted primarily of an increase a decrease in accounts receivable of $34.3 $14.0 million and a net increase in accounts payable and accrued expenses and other current liabilities of $17.7 million, partially offset by an increase in inventory of $8.4 $7.7 million and an increase in prepaid expenses and other current assets of $6.3 million, partially offset by an increase in accounts payable and accrued expenses and other current liabilities of $6.5 $3.8 million.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
A conditional conversion feature of the Notes was triggered on June 30, 2024 and again on September 30, 2024, December 31, 2025, as the last reported sale price of our common stock was greater than or equal to 130% of the conversion price of the Notes for at least 20 trading days during the period of 30 consecutive trading days ending on and including the last trading day of each of the quarters quarter ended June 30, 2024 and September 30, 2024, respectively, December 31, 2025, and the Notes therefore became convertible at the noteholders’ election in the immediately following calendar quarters ended September 30, 2024 and December quarter ending March 31, 2024, respectively. 2026 (and only during this calendar quarter).
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Other Interest income and other income (expense), net also included $1.0 million of realized and unrealized foreign currency transactions gains for the year ended December 31, 2025, and $0.7 million of realized and unrealized foreign currency transactions losses for the year ended December 31, 2024, and $0.3 million of realized and unrealized foreign currency transactions gains during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, 2025, we acquired eight 3 transplant-related fixed-wing aircraft with an aggregate purchase price of $109.6 million and we plan to acquire additional aircraft in 2025, including two aircraft purchased in January 2025 and February 2025 with an aggregate purchase price of $28.4 $42.9 million.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Department of Health and Human Services’ Health Resources and Services Administration, or HRSA, announced initiatives designed to improve the OPTN, including its intent to solicit contract proposals to manage the OPTN, which is currently operated by the United Network for Organ Sharing, or UNOS, OPTN under a multi-vendor model following the expiration of the sole-vendor contract that expired in between UNOS and HRSA on March 29, 2024.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 Change (in thousands) Personnel related (including stock-based $ 25,720 $ 21,927 $ 15,489 $ 6,438 3,793 compensation expense) Laboratory supplies and research materials 17,550 13,990 7,939 6,051 3,560 Consulting and third-party services 15,492 12,920 5,788 7,132 2,572 Clinical trials costs 1,459 478 1,077 (599) 981 Facility related and other 8,834 6,653 5,762 891 2,181 Total research, development and clinical $ 69,055 $ 55,968 $ 36,055 $ 19,913 13,087 trials expenses
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 Change (in thousands) Personnel related (including stock-based $ 114,506 $ 109,475 $ 72,717 $ 36,758 5,031 compensation expense) Professional and consultant fees 25,936 18,313 17,401 912 7,623 NOP support 6,826 12,289 11,985 304 (5,463) Tradeshows and conferences 4,316 4,328 4,575 (247) (12) Facility related and other 33,584 24,212 12,875 11,337 9,372 Total selling, general and administrative $ 185,168 $ 168,617 $ 119,553 $ 49,064 16,551 expenses
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, 2025, operating activities provided $48.8 $192.8 million of cash, primarily resulting from our net income of $35.5 $190.3 million and net non-cash charges of $58.3 million, partially offset by net cash used provided by changes in our operating assets and liabilities of $45.0 $18.4 million, partially offset by net non-cash income of $15.8 million.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 2022 (in thousands) Net cash provided by (used in) operating activities $ 192,840 $ 48,803 $ (13,028) $ (45,817) Net cash provided by (used in) used in investing activities (59,251) (129,303) (193,953) 54,513 Net cash provided by financing activities 16,857 22,874 400,418 167,927 Effect of exchange rate changes on cash, cash equivalents and 1,270 (536) 193 (1,021) restricted cash Net increase (decrease) in cash, cash equivalents and restricted cash $ 151,716 $ (58,162) $ 193,630 $ 175,602
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Total research, development and clinical trials expenses increased by $19.9 $13.1 million from $36.1 million in the year ended December 31, 2023 to $56.0 million in the year ended December 31, 2024. 2024 to $69.1 million in the year ended December 31, 2025.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
As we continue to pursue and increase commercial sales of our OCS products, we expect our costs and expenses to increase in the future, particularly as we expand our commercial team, grow our NOP, scale our manufacturing and sterilization operations, continue research, development and clinical trial efforts, including expanding our research and development and manufacturing capabilities in Italy, seek regulatory approval for the next generation OCS, new products and product enhancements, including new indications, both in the United States and in select non-U.S. markets, establish and relocate to a new long-term global headquarters, and seek greater control of air and ground transport for our NOP.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
United States Lung total revenue $ 13,443 $ 15,755 $ 10,548 $ 5,207 Heart total revenue 111,839 96,663 59,080 37,583 Liver total revenue 459,415 309,462 151,719 157,743 Total United States OCS transplant revenue 584,697 421,880 221,347 200,533 All other countries Lung total revenue 1,418 1,926 1,272 654 Heart total revenue 14,169 13,198 14,012 (814) Liver total revenue 1,113 158 104 54 Total all other countries OCS transplant 16,700 15,282 15,388 (106) revenue Total OCS transplant revenue $ 601,397 $ 437,162 $ 236,735 $ 200,427
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesMD&A
With the acquisition of Summit in August 2023, the purchase of fixed-wing transplant aircraft and the addition of a logistics team, we anticipate have increased service revenue from our transplant logistics services.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesMD&A
Through December 31, 2024, all of 2025, our sales outside of the United States have been commercial sales (unrelated to any clinical trials).
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesMD&A
For example, if If the demand for our products exceeds our existing manufacturing and sterilization capacity, our ability to fulfill orders would be limited until we have sufficiently expanded such operations.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new